27.7 C
Vientiane
Thursday, June 19, 2025
spot_img
Home Blog Page 780

3Z Pharmaceuticals Publishes Breakthrough Study on Shared Metabolic Pathways in ADHD Therapeutics

REYKJAVIK, Iceland, Feb. 24, 2025 /PRNewswire/ — 3Z Pharmaceuticals, a CNS-focused therapeutic development specialist, today announced the publication of a groundbreaking study in The Journal of Pharmacology and Experimental Therapeutics, unveiling novel insights into the metabolic mechanisms of ADHD treatments. This research, utilizing untargeted metabolomic and lipidomic profiling, addresses a critical knowledge gap in ADHD treatment. It reveals a convergence of molecular pathways among stimulant and non-stimulant ADHD medications and supports 3Z’s earlier announced discovery of amlodipine as an L-type calcium channel blocker candidate.

ADHD is a highly prevalent neurodevelopmental disorder with complex underlying mechanisms and limited treatment options. While both stimulant and non-stimulant medications are widely used, their precise metabolic effects on the brain remain poorly understood.

“This study represents a major leap forward in our understanding of ADHD therapeutics,” commented Dr. Karl Karlsson, CEO of 3Z Pharmaceuticals, emphasizing the study’s significance, “By leveraging advanced metabolomics and lipidomics, we have uncovered a shared metabolic signature across treatments—highlighting the potential of L-type calcium channel modulation as the foundation for a new non-stimulant ADHD therapy. These findings not only validate our drug discovery platform but also pave the way for much-needed new treatment options.”

To bridge this gap, 3Z Pharmaceuticals employed an advanced systems biology approach, integrating cross-species analysis using the zebrafish adgrl3.1 ADHD model with targeted metabolomic profiling to explore common metabolic pathways underlying ADHD therapeutics.

Key Findings from the Study:

  • Metabolic Pathway Convergence: The study demonstrated that existing ADHD treatments—methylphenidate, guanfacine, and atomoxetine—as well as the novel candidate amlodipine, modulate share metabolic pathways related to amino acid and lipid metabolism. These include glycine, serine, threonine, lysophosphatidylcholine, and sphingomyelin metabolism.
  • Systemic impact: Rather than acting through distinct, isolated mechanisms, ADHD medications appear to exert a broader, systemic impact on neurotransmitter precursors, oxidative stress markers, and energy metabolism.
  • Amlodipine’s Overlapping Effects with ADHD Medications: The metabolic profile of amlodipine significantly overlapped with that of established ADHD treatments, supporting L-type calcium channel engagement as a potential therapeutic pathway for ADHD.

Full Study: https://www.sciencedirect.com/science/article/pii/S0022356525396163 

Building on these findings, 3Z Pharmaceuticals is advancing its metabolomics-driven approach to CNS drug discovery, focusing on refining therapeutic targets and optimizing treatment strategies for future clinical development.

About 3Z Pharmaceuticals

3Z Pharmaceuticals, based in Reykjavik, Iceland, identifies and advances next-generation therapies for CNS disorders through both novel discovery and strategic repurposing. The company is pioneering a state-of-the-art drug development platform that integrates high-throughput screening, multi-omics, and AI analytics.

With a strong focus on translational validation, 3Z de-risks CNS drug development by combining multi-species assessment with human Mendelian randomization, polygenic risk scoring, and genetic studies to enhance clinical predictability.

Contact

For more information or media inquiries, please contact:

Karl Karlsson
CEO, 3Z Pharmaceuticals
Karlsson@3z.is
DD: +354 825 66467

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/3z-ehf/r/3z-pharmaceuticals-publishes-breakthrough-study-on-shared-metabolic-pathways-in-adhd-therapeutics,c4110316

Captiva Verde Welcomes Elder Sir Dr. Joe Michael to Matnaggewinu Development Corp (MDC) Advisory Board

VANCOUVER, BRITISH COLUMBIA – Newsfile Corp. – 24 February 2025 – Captiva Verde Wellness Corp. (CSE: PWR) (OTC Pink: CPIVF) (“Captiva Verde”) a public company listed on the Canadian Securities Exchange under the trading symbol PWR and further listed in the US OTC Market under the symbol CPIVF is proud to announce that Elder Sir Joe Michael, a highly respected leader within the Mi’kmaw Nation and Indigenous communities across Canada, has joined the Advisory Board of Matnaggewinu Development Corp (MDC).

Elder Joe Michael, also known as “Dr. Joe Mike” brings decades of leadership, cultural wisdom, and advocacy for Indigenous communities, which will be invaluable to MDC’s mission of fostering Indigenous-led economic development and community empowerment.

Elder Joe Michael was awarded an Honorary Doctor of Humanities from Acadia University in 2019 in recognition of his lifelong dedication to community service, cultural preservation, and leadership. He was notably the first Mi’kmaw member of the Royal Canadian Mounted Police (RCMP), where he served for 25 years. Throughout his distinguished career, he bridged traditional Mi’kmaw knowledge with contemporary policing practices, leading to the development of the RCMP’s Aboriginal Community Policing model, which remains an integral part of cadet training at the RCMP Depot in Regina. As Detachment Commander, he also held the esteemed role of the RCMP’s Pipe Carrier, performing sacred ceremonies and fostering cross-cultural understanding.

Most recently, Elder Joe was appointed to the Mi’kmaq Grand Council, the traditional governing body representing Mi’kmaw people, where he serves as a Captain (Keptin). His work on the council focuses on strengthening community connections, preserving Mi’kmaw history, and advocating for the well-being of Indigenous people in the region. His recent knighthood from the Order of St. George, where he was honored with the title “Chevalier Joe Michael,” further underscores his lifelong commitment to “faith, service, and honor.”

“Having Elder, Sir Joe Michael join the MDC Advisory Board is both an honor and a significant milestone for us,” said Jeff Ciachurski. “His extensive leadership experience, profound cultural insights, and deep connection to the Mi’kmaq Nation will guide MDC as we continue to develop initiatives that honor Indigenous traditions while advancing meaningful economic reconciliation and creating equitable opportunities for Indigenous communities.”

Elder Joe’s appointment reinforces MDC’s commitment to culturally grounded leadership and highlights Captiva Verde’s dedication to supporting Indigenous-led development projects through meaningful collaboration and community engagement.

“Joining the MDC Advisory Board is a generational opportunity to accelerate a new future where First Nations communities and businesses are equitably participating in Canada’s open trading economy, including new sectors like aviation and military equipment,” said Elder Sir Joe Michael. “I am proud to support a Mi’kmaq company that is breaking new ground and creating meaningful opportunities for our people.”

On Behalf of the Board of Directors

“Jeff Ciachurski”
Jeffrey Ciachurski
Chief Executive Officer and Director
Cell: (949) 903-5906
E-mail: westernwind@shaw.ca

The issuer is solely responsible for the content of this announcement.

About Matnaggewinu Development Corp (MDC):

MDC is an Indigenous-owned organization focused on creating sustainable economic opportunities for Mi’kmaw communities through strategic partnerships and community-driven initiatives. Matnaggewinu is 49% owned by Captiva Verde.

About Captiva Verde:

Captiva Verde is dedicated to supporting innovative, community-based projects that drive sustainability, economic development, and cultural preservation across Canada. Matnaggewinu (MDC) is 49% owned by Captiva Verde.

Neither Canadian Securities Exchange nor its regulation services provider accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward Looking Information

This news release includes “forward-looking statements” and “forward-looking information” within the meaning of Canadian securities laws and United States securities laws (together, “forward-looking statements”). All statements included in this news release, other than statements of historical fact, are forward-looking statements including, without limitation, statements with respect to the expansion of Captiva’s health and wellness platform.

Forward-looking statements include predictions, projections and forecasts and are often, but not always, identified by the use of words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, “potential”, “target”, “budget”, “propose” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions and includes the negatives thereof.

Forward-looking statements are based on a number of assumptions and estimates that, while considered reasonable by management based on the business and markets in which the Company operates, are inherently subject to significant operational, economic, and competitive uncertainties, risks and contingencies. These include assumptions regarding, among other things: general business and economic conditions. There can be no assurance that forward-looking statements will prove to be accurate and actual results, and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include those described under the heading “Risks and Uncertainties” in the Company’s most recently filed MD&A (a copy of which is available under the Company’s SEDAR profile at ). The Company does not undertake to update or revise any forward-looking statements, except in accordance with applicable law.

NETSCOUT Applauded by Frost & Sullivan for Enabling Real-Time Visibility into Network Traffic with Competitive Strategies

NETSCOUT’s solutions provide actionable intelligence through powerful deep packet inspection, behavioral analytics, and AI-driven insights

SAN ANTONIO, Feb. 24, 2025 /PRNewswire/ — Frost & Sullivan recently assessed the next-generation application and network visibility platform industry and, based on its findings, recognizes NETSCOUT with the 2025 Global Competitive Strategy Leadership Award. The company’s Visibility Without Borders strategy has proven effective in solidifying its position in the network visibility and cybersecurity markets. This strategy builds on its nGeniusONE portfolio, including its nGenius Enterprise Performance Management solution that provides real-time network traffic visibility across all deployments, Omnis Cyber Intelligence that uses scalable deep packet inspection (DPI) to enable real-time threat detection and historical investigation mitigation, and Arbor Edge Defense that provides comprehensive DDOS attack detection and mitigation. The comprehensive visibility solution operates across cloud, on-premises (including remote locations), and hybrid environments. Complex organizations, including 90% of the US Fortune 100, utilize the solution for consistent monitoring, service assurance, threat detection and DDoS protection across distributed networks.

NETSCOUT’s effective strategy stems from its focus on breaking down operational silos and enabling data sharing, which supports critical functions such as SecOps, NetOps, and AIOps. This has led to measurable improvements in mean time to resolution (MTTR) and operational efficiency, as seen by some of its largest customers across telco, BFSI, and government sectors. The company’s strategic focus on providing Visibility Without Borders has strengthened its market position, expanded customer mindshare, and proved its effectiveness in meeting the evolving needs of digitally complex organizations. NETSCOUT has executed its strategy in the next-generation visibility market by leveraging strategic acquisitions, conducting continuous product innovation, and securing key client wins with its Smart Data technology that transforms raw packet data into actionable intelligence. This helps organizations gather deep insights into network performance, application performance and security threats across their entire IT infrastructure.

Vinay Biradar, principal consultant for security advisory at Frost & Sullivan, observed, “The key differentiator for NETSCOUT lies in its multi-dimensional scalability and deployment flexibility. By supporting both hardware and virtual solutions through InfiniStream/CyberStream/Arbor Edge Defense and vSTREAM/vCyberStream/vArbor Edge Defense products, NETSCOUT empowers large enterprises and government agencies to deploy visibility tools efficiently across diverse infrastructure. This capability is especially relevant for industries where network complexity demands robust and scalable solutions.”

NETSCOUT’s ability to offer comprehensive visibility into multi-cloud environments, east-west traffic for cybersecurity, service assurance, and monitoring has been a significant competitive differentiator that continues to help it win large deals across enterprises and telecom providers. Its customers consistently value the company’s next-generation products’ ability to simplify operations, reduce risks, enhance performance, and maintain trust in increasingly digital-first operations to deliver reliable outcomes across complex IT deployments. NETSCOUT’s customer service and robust technical assistance help its diverse clientele troubleshoot and optimize product deployment, maximizing ROI. The company has strategically invested in its brand equity through continuous product innovation and expanding its customer base. Additionally, NETSCOUT’s AI/ML integration, cloud-native solutions, and partnerships with leading providers like Cisco and VMware have reinforced its image as an innovative and reliable digital transformation partner. Through these efforts, NETSCOUT has effectively built and sustained a strong brand that resonates with existing and potential customers, ensuring its continued growth and market leadership.

“NETSCOUT consistently provides the right solutions for its customers, aligning technology with customer goals. Customer feedback highlights the company’s proactive approach, scalable solutions, and expertise in addressing modern IT challenges. With continued innovation, commitment to customer success, and market expansion into 5G and multi-cloud network visibility, the company is poised for sustained growth and leadership,” added Vinay. With its strong product innovation, substantial brand equity, proven customer value, and strong overall performance, NETSCOUT earns Frost & Sullivan’s 2025 Global Competitive Strategy Leadership Award in the Next Generation Visibility Platform industry.

Each year, Frost & Sullivan presents this award to the company that has leveraged competitive intelligence to successfully execute a strategy that results in stronger market share, competitive brand positioning, and customer satisfaction.

Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact us: Start the discussion.

Contact:

Ashley Shreve
E:ashley.shreve@frost.com

About NETSCOUT

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) protects the connected world from cyberattacks and performance and availability disruptions through its unique visibility platform and solutions powered by its pioneering deep packet inspection at scale technology. NETSCOUT serves the world’s largest enterprises, service providers, and public sector organizations. Learn more at www.netscout.com  or follow @NETSCOUT on LinkedIn, X, or Facebook.

China Auto Valley • Wuhan-made Auto Brands Gather at Global Launch Event

WUHAN, China, Feb. 24, 2025 /PRNewswire/ — A report from Changjiang Daily.

VOYAH Ultra-Fast Charging Station Tops Global Speed Rankings

On February 23, the Chinese Auto Valley • Press Conference on the Global Launch of Wuhan-Made Auto Brands was held at Dongfeng Motor Global Innovation Center. Brands including Voyah, Dongfeng Honda, Dongfeng M-Hero, Lotus Cars, Dongfeng eπ, Dongfeng Aeolus, and Dongfeng Nammi formed a brand cluster to make their first collective appearance to showcase the innovation capabilities of Wuhan-made vehicles in the era of automotive intelligence.

Dongfeng Motor Global Innovation Center
Dongfeng Motor Global Innovation Center

Auto Valley to launch 1 to 2 new models quarterly over next three years

At the press conference, leader of the Wuhan Economic & Technological Development Zone announced that China’s Auto Valley has established a comprehensive vehicle matrix spanning mainstream, premium, and luxury segments. Over the next three years, the region will release 1 to 2 new models per quarter, including PHEV, EREV, BEV, and hydrogen-powered vehicles, covering price ranges from 50,000 yuan to 1 million yuan

Voyah will “go all-in on intelligent technology” in 2024, becoming China’s first automaker to equip its full lineup (SUVs, MPVs, sedans) with Huawei’s Qiankun intelligent driving system and Harmony cockpit operating system, aiming to hit its annual sales target of 200,000 units. To address range anxiety, Voyah has developed the world’s first megawatt-level ultra-fast charging station, “Voyah VP1000,” achieving a 1.7 km range per second of charging (15-minute charge for 515 km range)—the world’s fastest charging speed. 

The Dongfeng Honda S7, Wuhan’s first locally built premium electric SUV, will make its fully electric debut in early March 2024.

By late February, Lotus will roll out urban NOA (Navigation on Autopilot) in 16 Chinese cities, solidifying its status as the only million-RMB luxury sports brand globally to implement mapless NOA technology.

In H1 2025, Dongfeng M-Hero will launch the M-Hero 917 Extended Edition (high-end customization), while in H2 2025, a new intelligent electric off-roader co-developed with Huawei’s full-stack tech will debut. Previously, M-Hero has collaborated with luxury brand Lorinser to create a M-Hero M800 Stellar Armored Vehicle. It has also collaborated with the movie Operation Leviathan to debut China’s first movie co-branded vehicle M-Hero 917 Dragon Armor Edition. These models have built M-Hero’s current lineup spanning from 600,000 to 1,000,000 yuan.

Dongfeng has unified management of three brands: Dongfeng Aeolus, Dongfeng eπ, and Dongfeng Nammi. Over the next three years, they will launch 30 new models, including Nammi 06. There will also be upcoming debut of 2025 refreshes of eπ007 and eπ008, as well as a new Aeolus PHEV.

Voyah to achieve near-full coverage in European markets by next year

This year, Dongfeng’s brands are fully committed to expanding their global presence.

Voyah has consistently pursued a “premium globalization strategy”. Li Boxiao, Deputy General Manager of Voyah’s Sales and Service Company, revealed that by 2026, Voyah will achieve near-complete coverage across European countries, complete strategic deployments in Central Asia, the Middle East, as well as Central and South America. It will also enter right-hand drive markets. “By 2030, cumulative overseas sales will exceed 500,000 units,” he stated.

Rooted in Wuhan, Dongfeng M-Hero is expanding nationwide and globally. Tao Haiying, Brand Operations Director of Dongfeng M-Hero Technology, highlighted that the brand has successfully entered high-end markets such as Switzerland, the UAE, and Qatar, offering “custom-tailored” products and services for global consumers.

2025 marks Lotus’ ‘Year of Brand’,” said Qiao Xinyu, Vice President of the brand’s marketing section. The automaker will leverage iconic milestones including the 40th anniversary of Ayrton Senna’s championship, the 50th anniversary of the Esprit model, and the 75th anniversary of Lotus’ first F1 victory, to amplify its brand appeal.

This year, Wuhan Economic & Technological Development Zone will kick off the “Auto Valley Made • Global Journey,” a 2025 automotive roadshow series to boost consumption. Featuring three themes Jingchu Tour, China Tour, and Global Tour, the campaign will host 18 tour events. Auto brands under Dongfeng, including Voyah, M-Hero, eπ, and Honda, will embark from Wuhan on tours nationwide and worldwide.

Double subsidies for Dongfeng vehicle purchases in 2025

During the event, it was announced that an auto purchase voucher program will continue to be issued this year, with subsidies doubled for consumers.

From January 1 to December 31, 2025, consumers purchasing eligible models, including both new energy vehicles (NEVs) and fuel-powered vehicles, under the brands VOYAH, Dongfeng M-Hero, Dongfeng eπ, Dongfeng Aeolus, Dongfeng Honda, and Lotus, within Hubei Province will enjoy doubled subsidies, namely the tiered incentives increase from 2024’s original amounts of 1,000/2,000/4,000 yuan to 2,000/4,000/6,000 yuan. Additionally, auto purchase vouchers can be stacked with national, provincial, and municipal consumption-boosting policies for maximum benefits.

 

LabConnect and Australian Clinical Labs’ Specialised Trials Announce Strategic Partnership in Australia and Asia Pacific Region

PORT MELBOURNE, Australia and JOHNSON CITY, Tenn., Feb. 24, 2025 /PRNewswire/ — LabConnect and Australian Clinical Labs’ (ACL) Specialised Trials have forged a strategic partnership to expand support of clinical trials in Australia and the Asia-Pacific region.

This exclusive, multi-year agreement solidifies the partnership, and enables both organizations to leverage complementary strengths to help get patients the medicines they need by meeting the growing regional demand of clinical trial support services for pharmaceutical, biotechnology, and clinical research organizations.

ACL Specialised Trials is one of the leading clinical trials laboratories in Australia, managing large biotech and pharmaceutical clinical trials from Phase 1 to Phase 4 studies. With a vast network of laboratories across Australia, ACL Specialised Trials has extensive experience in delivering end to end pathology solutions and a wide range of clinical trials central laboratory services for national, multi-site and single site clinical trial studies. 

“This long-term partnership will help global clients access Australian patients and bring key international trials to this part of the world – ultimately resulting in the advancement of leading-edge medical breakthroughs that can save lives and improve patient outcomes,” stated ACL Group Executive CEO, Melinda McGrath. “It will strengthen our position as a key player in a growing $8 billion market and I am excited to showcase our depth of experience and talented team on the world stage. This is fantastic news for our communities, and we are proud to be partnering with LabConnect.”

As the world’s most agile central laboratory solutions partner, LabConnect will leverage ACL’s extensive test menu with a comprehensive range of services to support the region including in-country lab kit building, biospecimen management, project and data management, and logistics support. Catherine Osborne, APAC General Manager, leads LabConnect’s growing operations and business in the region.

As LabConnect’s primary laboratory services provider for Australia and the broader APAC region, ACL Specialised Trials will support LabConnect with their dedicated, clinical trials laboratory and project team situated in Port Melbourne, Victoria, serving as the operational hub for the region. 

Wes Wheeler, LabConnect CEO, added, “Our clients increasingly include Asian Pacific investigative sites in their clinical development plans and our partnership with ACL Specialised Trials provides us with a platform from which we can deliver our comprehensive suite of industry-leading central laboratory services across the region.”

About ACL Specialised Trials

Specialised Trials is a subsidiary of Australian Clinical Labs, showcasing our commitment to improving patient lives through medical excellence, market-leading technology and a talented team of experts. ACL Specialised Trials offers a dedicated pathology approach to Phase I-IV clinical trials, delivering quality solutions for our clients. Our state-of-the-art, purpose-built facility and years of experience with commercial and clinical trials ensures a seamless transition from initial inquiry through to delivery.

Visit us at specialisedtrials.com.au
Follow us on LinkedIn

About LabConnect

LabConnect is the world’s most agile central laboratory solutions partner, providing technology-driven, customized, orchestrated, and scalable support services for clinical trials of all sizes and complexity. With over 20 years experience and 1,900+ clinical studies across 93 countries, LabConnect is the trusted partner for biotechnology, pharmaceutical, and clinical research organizations.

With modern operations and strategic alliances with world-leading laboratories, LabConnect is uniquely positioned to provide access to the latest innovation and automation. LabConnect delivers exceptional service with a comprehensive suite of central laboratory solutions including custom lab kits, advanced sample tracking and integrated logistics, global standardized sample processing, industry-leading testing menu of 10,200+ validated assays, worldwide support for radiopharmaceuticals, and next-generation biorepository.

LabConnect scientific experts support pre-clinical and clinical studies with scientific project management, bioanalytical and biospecimen management, biomarker strategy and logistics solutions. LabConnect excels at data management, integrating complex datasets from diverse sources into a single, cohesive, submission-ready dataset.

Follow LabConnect on LinkedIn
Learn more at labconnect.com

Photo – https://laotiantimes.com/wp-content/uploads/2025/02/labconnect_and_australian_clinical_labs_specialised_trials_partnership.jpg
Logo – https://laotiantimes.com/wp-content/uploads/2025/02/labconnect_logo-1.jpg

Risen Storage to Showcase New Flexible Energy Storage System “eFlex” at Japan’s “World Smart Energy Week 2025”

TOKYO, Feb. 24, 2025 /PRNewswire/ — Risen Storage was excited to unveil its latest flexible product “eFlex” at World Smart Energy Week 2025 in Tokyo on February 19, 2025. This advanced system is a flexible solution with an 836 kWh minimum building block and can be configured to a system with up to 6.7MWh capacity which designed for international markets, specifically targeting Europe, North America, and Japan, offering enhanced performance, flexibility, and adaptability to meet the diverse energy needs of these regions.


Maximizing Energy Density and Space Utilization:
The newly launched “eFlex” energy storage system delivers efficient performance with its compact design, maximizing land use. Its high energy density and liquid cooling technology ensure optimal performance and minimal space requirements, making it ideal for areas with limited land.

Convenient Transportation and Installation:
Designed for regions with challenging infrastructure like rural Europe, Africa, North America, the Caribbean, and Japan, the system ensures smooth delivery across various terrains. Its modular and liquid-cooled design enables flexible installation, reducing time and costs, suitable for both urban and rural settings.

Exceptional Adaptability:
The liquid-cooled system operates efficiently from -40°C to 55°C, ensuring reliable performance in diverse climates across Europe, North America, and Japan. With strong seismic resistance and IP55 protection, it is built to withstand harsh environments, offering long-term stability.

Flexibility and Modularity:
The system supports parallel connections of 6-8 units, offering customizable capacities from 836kWh to 6.7MWh per system. Its modular design reduces energy consumption and boosts overall system efficiency.

Comprehensive Certifications and High Safety Standards:
The system meets international certifications such as UL9540, UL9540A, CE, and NFPA 68/69, ensuring top safety standards. Equipped with MSD fuses, explosion-proof valves, and intelligent BMUs, it guarantees long-term reliability and safety, backed by Risen Storage’s commitment to quality.

About Risen Storage
Risen Storage has 19 years of experience in lithium battery solutions, specializing in PCS, BMS, EMS, C&I, and large-scale BESS. Its Energy Storage Battery System is the first in China to pass UL9540A certification in both the US and China. With a production capacity over 15 GWh, Risen Storage has deployed large-scale projects globally, delivering over 100 MW and earning worldwide recognition for quality and service.

Visionary Holdings Navigates a New Era of Precision Medicine, Achieving Major Breakthroughs in Targeted Therapy

TORONTO, Feb. 24, 2025 /PRNewswire/ — In today’s era of rapid technological advancement, the deep integration of artificial intelligence and the medical field is bringing unprecedented hope to human health. Among these advancements, targeted therapy, a cornerstone of precision medicine, is gradually reshaping the treatment landscape for cancer and other major diseases with its unique advantages. Visionary Holdings (Nasdaq Stock Code: GV), a globally influential multinational corporation, stands at the forefront of this medical revolution, leading targeted therapy to new heights.

Targeted therapy, an innovative treatment based on molecular biology, precisely targets diseased cells while sparing healthy ones, significantly improving treatment efficacy and reducing the side effects associated with traditional radiotherapy and chemotherapy. Drugs like Erlotinib for EGFR-mutated non-small cell lung cancer and Herceptin for HER2-positive breast cancer have markedly improved patient survival rates. With the progress of precision medicine, targeted therapy is not only excelling in cancer treatment but is also expanding into areas such as neurodegenerative diseases and autoimmune disorders. According to McKinsey Global Institute, the global biopharmaceutical market is projected to exceed $1.5 trillion by 2030, with the precision medicine sector expected to grow at a compound annual growth rate (CAGR) of over 10%, indicating a highly promising future for targeted therapy.

Visionary Holdings has keenly recognized the immense potential of the biopharmaceutical field and has actively invested in cutting-edge areas such as tumor-targeted therapy, gene sequencing, AI-assisted drug development, and liquid biopsy. The company is focused on advancing next-generation immunotherapies, gene editing, and precision oncology, enhancing biomarker detection and liquid biopsy technologies, and leveraging AI to accelerate drug development. It has also successfully developed rapid at-home testing technologies for cervical and colorectal cancers, increasing cancer screening coverage and providing significant convenience for early diagnosis.

In practical terms, Visionary Holdings has driven substantial breakthroughs in targeted therapy through a series of strategic investments and collaborations. The company has made strategic investments in leading biotech firms to co-develop third-generation EGFR inhibitors aimed at overcoming drug resistance in non-small cell lung cancer patients. This drug is currently in global clinical trials and has garnered widespread attention. Additionally, Visionary Holdings has partnered with top gene sequencing companies to develop liquid biopsy technologies, enabling real-time monitoring of cancer progression through non-invasive blood tests, making treatments more precise and efficient.

Furthermore, Visionary Holdings has collaborated with numerous global biotech leaders, AI pharmaceutical giants, and medical research institutions to pioneer innovative projects. In targeted drug development, the company is focusing on specific gene mutations such as HER2, BRAF, and KRAS to develop next-generation anticancer drugs. By utilizing AI drug discovery technologies, deep learning algorithms are employed to analyze protein structures, significantly speeding up drug screening and optimization. Its global clinical trial network spans North America, Europe, and Asia, accelerating the time-to-market for new drugs and benefiting more patients.

Looking ahead, the combination of targeted therapy and immunotherapy will become a trend, and AI will be deeply integrated into precision medicine, substantially shortening drug development cycles and reducing costs. The application scope of targeted therapy will continue to expand, offering hope to patients with a wider range of diseases. Visionary Holdings will continue to leverage its cutting-edge technology, strategic vision, and global collaboration network to deepen its commitment to targeted therapy and precision medicine. The company is dedicated to developing next-generation targeted drugs, improving global patient access to advanced treatments, leading the new era of precision medicine, and writing a new chapter in the pursuit of human health.

For more information, please contact:

Visionary Holdings Inc.
Investor Relations Department
Email: ir@farvision.ca 

Air Premia Enhances Flight Safety with IATA Turbulence Aware

  • Air Premia to Adopt IATA Turbulence Aware Starting March 1, 2025
  • Real-Time Turbulence Data to Enhance Safety and Passenger Comfort

SEOUL, South Korea, Feb. 24, 2025 /PRNewswire/ — Air Premia (CEO Kim Jae-hyun, Yoo Myung-sub) announced today that it will introduce IATA Turbulence Aware, a cutting-edge safety tool developed by the International Air Transport Association (IATA), starting on March 1, 2025. This advanced system leverages real-time in-situ turbulence reports to enhance flight safety and passenger comfort. As of the end of last year, more than 25 airlines worldwide were contributing and utilizing Turbulence Aware data across more than 2,600 aircraft. By accessing real-time turbulence information, Air Premia’s flight crews will be better equipped to avoid or mitigate the effects of turbulence, ensuring safer and smoother flights.

According to the Ministry of Land, Infrastructure, and Transport, airlines experienced 14,802 turbulence encounters in the first half of 2024, marking a 78% increase compared to five years ago. By adopting Turbulence Aware, Air Premia can shift from a forecast-based response to a real-time response, thereby improving its ability to secure safer flight paths.

The implementation of Turbulence Aware will enable Air Premia to effectively respond to Clear Air Turbulence (CAT) in airspace where turbulence was not predicted, and to adjust flight operations when predicted turbulence does not occur, reducing safety incidents for both passengers and crew.

In addition to joining the platform, Air Premia is committed to safety by sharing turbulence information in pre-flight briefings with flight and cabin crew, adjusting service timings for passengers, and introducing GE Aerospace’s flight data monitoring system, ‘Safety Insight,’ to identify and manage potential risks during flights.

Koh Yoon Beom, Director of Safety & Security Division at Air Premia, stated, “By adopting IATA Turbulence Aware, we can strengthen customer trust and enhance our safety image. We are dedicated to providing a safe and comfortable flying experience for our passengers.”

Dr. Xie Xingquan, IATA’s Regional Vice President for North Asia and Asia Pacific (ad interim) said: “We welcome the participation of Air Premia in Turbulence Aware. Making use of accurate and up-to-date data in Turbulence Aware helps flight crews’ efforts to avoid or at least mitigate the effects of turbulence. The quality of this data improves with each new contributing airline. Air Premia’s contribution will help the industry improve the safety and comfort of crew and passengers alike.”

About Air Premia
Air Premia is Korea’s only Hybrid Service Carrier (HSC), offering high-quality services at reasonable prices based on its unique philosophy of providing essential premium services.